Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
-
Published:2022-01
Issue:1
Volume:97
Page:26-30
-
ISSN:0025-6196
-
Container-title:Mayo Clinic Proceedings
-
language:en
-
Short-container-title:Mayo Clinic Proceedings
Author:
Razonable Raymund R.ORCID,
Ganesh RavindraORCID,
Bierle Dennis M.
Funder
Gilead Sciences
Mayo Clinic
Reference7 articles.
1. Public Health Scotland and the EAVE II Collaborators. Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern, June-July, 2021;Shah;Lancet Digit Health,2021
2. Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19;Weinreich;N Engl J Med,2021
3. A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic model;Razonable;Mayo Clin Proc,2021
4. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19;Ganesh;J Clin Invest,2021
5. Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19;Razonable;EClinicalMedicine,2021
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献